Patients with LCA due to RPE65 mutations (5–10%) can benefit from Luxturna (Spark Therapeutics, Inc., Philadelphia, PA, USA), which delivers a functional RPE65 gene. Here, RPE65 is linked to Leber congenital amaurosis.